Actively Recruiting
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Led by Alexion Pharmaceuticals, Inc. · Updated on 2026-02-05
40
Participants Needed
23
Research Sites
99 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
CONDITIONS
Official Title
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of myasthenia gravis confirmed by positive anti-AChR antibody test and one of the following: abnormal neuromuscular transmission test, positive anticholinesterase test, or improvement with cholinesterase inhibitors
- Disease duration of 3 years or less at enrollment
- MGFA class IIb to IV
- Eligible for Ravulizumab treatment based on reimbursement criteria
- Completed Neisseria meningitidis vaccination at least two weeks before treatment or received antibiotic prevention as recommended
You will not qualify if you...
- Unable to understand or sign informed consent
- Hypersensitivity to Ravulizumab or its components
- Contraindication to the study product
- Previous treatment with C5 inhibitors
- Rituximab infusion within 6 months prior to enrollment
- FcRn blocker infusion within 3 months prior to enrollment
- Pregnant, breastfeeding, or planning pregnancy during the study
- Planning to relocate during the study
- Uncertain about following the visit schedule
- Unable to complete questionnaires
- Previous or current participation in other interventional studies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 23 locations
1
Clinical Trial Site
Bergamo, Italy
Actively Recruiting
2
Clinical Trial Site
Bologna, Italy
Not Yet Recruiting
3
Clinical Trial Site
Bologna, Italy
Actively Recruiting
4
Clinical Trial Site
Brescia, Italy
Actively Recruiting
5
Clinical Trial Site
Florence, Italy
Actively Recruiting
6
Clinical Trial Site
Imperia, Italy
Not Yet Recruiting
7
Clinical Trial Site
Lecco, Italy
Actively Recruiting
8
Clinical Trial Site
Messina, Italy
Not Yet Recruiting
9
Clinical Trial Site
Milan, Italy
Actively Recruiting
10
Clinical Trial Site
Milan, Italy
Not Yet Recruiting
11
Clinical Trial Site
Naples, Italy
Not Yet Recruiting
12
Clinical Trial Site
Novara, Italy
Not Yet Recruiting
13
Clinical Trial Site
Orbassano, Italy
Not Yet Recruiting
14
Clinical Trial Site
Padova, Italy
Not Yet Recruiting
15
Clinical Trial Site
Palermo, Italy
Not Yet Recruiting
16
Clinical Trial Site
Parma, Italy
Actively Recruiting
17
Clinical Trial Site
Pavia, Italy
Not Yet Recruiting
18
Clinical Trial Site
Pisa, Italy
Not Yet Recruiting
19
Clinical Trial Site
Roma, Italy
Not Yet Recruiting
20
Clinical Trial Site
Salerno, Italy
Not Yet Recruiting
21
Clinical Trial Site
San Giovanni Rotondo, Italy, 71013
Actively Recruiting
22
Clinical Trial Site
Sassari, Italy
Actively Recruiting
23
Clinical Trial Site
Torino, Italy
Not Yet Recruiting
Research Team
A
Alexion Pharmaceuticals, Inc. (Sponsor)
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here